A Study of Nivolumab Plus Ipilimumab in Combination With Chemotherapy vs Chemotherapy Alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase III
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms CheckMate 9LA
- Sponsors Bristol-Myers Squibb
- 11 Aug 2017 Planned End Date changed from 15 Apr 2020 to 25 May 2020.
- 11 Aug 2017 Status changed from not yet recruiting to recruiting.
- 14 Jul 2017 New trial record